Clinical Trial Update: Efficacy and Safety of Brodalumab in Adolescents From 12 to 17 Years of Age With Moderate-to-severe Plaque Psoriasis [Phase 3]

View source ↗

Summary

Phase 3 trial results (efficacy and safety) for brodalumab in adolescents aged 12 to 17 with moderate-to-severe plaque psoriasis; the study was terminated, with…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plaque Psoriasis
• Psoriasis

Drugs mentioned

• brodalumab (brodalumab)

Snippet

Sponsor: LEO Pharma | Conditions: Psoriasis | Phase 3 | Status: TERMINATED | Results posted: 2024-02-28